--- title: "MNTN, Inc. Class A Signals Profitable Growth Ahead" type: "News" locale: "en" url: "https://longbridge.com/en/news/285292141.md" description: "MNTN, Inc. Class A reported strong Q1 earnings with a 14.3% revenue growth year-over-year, reaching $141.2 million. Adjusted EBITDA nearly doubled to $17 million, with full-year guidance of $96-$101 million. Gross margins improved to 77.4%. The pain management segment grew 28%, while minimally invasive ablation faced challenges. International revenue rose 11.5%, despite regional headwinds. Management is cautiously onboarding customers to ensure profitability. Overall, the company remains optimistic about future growth, driven by product adoption and regulatory approvals." datetime: "2026-05-06T01:20:53.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285292141.md) - [en](https://longbridge.com/en/news/285292141.md) - [zh-HK](https://longbridge.com/zh-HK/news/285292141.md) --- # MNTN, Inc. Class A Signals Profitable Growth Ahead MNTN, Inc Class A ((MNTN)) has held its Q1 earnings call. Read on for the main highlights of the call. ### Claim 55% Off TipRanks - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks MNTN, Inc. Class A’s latest earnings call painted a broadly upbeat picture, with strong top-line growth, expanding margins and accelerating trial activity offsetting a few visible weak spots. Management acknowledged declines in minimally invasive ablation and some international softness, but framed these as manageable headwinds against a diversified, innovation-led growth story. ## Revenue Growth Fuels Confidence Worldwide revenue reached about $141.2 million in Q1 2026, rising 14.3% year over year and 12.8% on a constant currency basis. U.S. sales climbed 14.9% to $116.2 million, although sequential growth versus Q4 2025 was modest at roughly 1%, putting more pressure on future quarters to deliver the planned acceleration. ## Profitability and EBITDA Nearly Double Profitability improved sharply, with adjusted EBITDA hitting $17 million, nearly double the level from the prior-year quarter. Management backed this performance with full-year adjusted EBITDA guidance of $96 million to $101 million, signaling confidence that operating leverage will continue as revenue scales. ## Gross Margins Expand on Mix and Cost Actions Gross margin expanded to 77.4% for 2026, up about 246 basis points versus 2025, reflecting structural improvements in the business. Management also pointed to a recent quarter achieving an 81% gross margin, helped by a favorable revenue mix and lower creative and hosting costs flowing through cost of goods. ## Clinical Trial Enrollment Races Ahead of Plan The BOX NOAF randomized trial is enrolling faster than expected, with around 300 of 960 patients signed up since starting in Q4 last year. The company now expects to complete enrollment around year-end, nearly one year ahead of the original schedule, potentially pulling forward evidence that could support broader adoption. ## Pain Management Franchise Leads the Pack Pain management emerged as a standout, delivering a 28% year-over-year increase and U.S. pain sales of $22.4 million, up about 29.5%. The Cryosphere and Cryo Max Pro devices were key drivers, making up roughly 70% of pain management revenue and underscoring the segment’s role as a growth engine. ## Strength in Open Ablation and Appendage Management Open ablation and appendage management continued to grow steadily, reinforcing the company’s cardiac franchise. Worldwide open ablation revenue climbed about 15%, with U.S. sales up 17.3% to $39.1 million, while appendage management rose roughly 16% globally, including $48.4 million in U.S. sales up 14.9%. ## Regulatory Wins and Product Launch Pipeline Regulatory progress added another leg to the growth story, highlighted by CE Mark approval for AtriClip Flex Mini and Pro Mini under the EU MDR. The company expects launches later this year across Europe and cited multiple new product introductions across the U.S., China and Japan as additional catalysts. ## International Growth Despite Regional Headwinds International revenue reached $25.0 million, up 11.5% on a reported basis and 3.3% in constant currency, showing resilience despite mixed conditions. Europe grew 13.2% to $16.1 million and Asia Pacific and other markets rose 8.4% to $8.9 million, even as distributor softness and U.K. uncertainty capped upside. ## Product Adoption Bolsters Competitive Position Management emphasized strong product uptake as a key driver of share gains, citing sustained adoption of the Encompass clamp and robust demand for AtriClip Flex Mini and Pro Mini. Growing traction for Cryo XD therapy was also highlighted, reinforcing the message that differentiated technology is helping the company outcompete rivals. ## Weakness in Minimally Invasive Ablation Not all segments performed equally, with U.S. minimally invasive ablation revenue falling about 25% year over year to $6.4 million. Management described the MIS ablation franchise as facing headwinds, signaling a need for renewed commercial focus or innovation to stabilize this piece of the portfolio. ## International Market Challenges Temper Upside While international revenue grew overall, management underscored ongoing uncertainty in the U.K. and weaker distributor sales in parts of Asia. These factors limited the upside in non-direct markets, suggesting that international performance may remain somewhat uneven even as core geographies expand. ## Sequential Momentum Remains Modest Sequential revenue growth was modest, with worldwide sales up roughly 1% versus Q4 2025, a pace that may not be sufficient on its own to support ambitious guidance. Investors will likely watch the coming quarters closely for signs that growth can re-accelerate, particularly in the second half of the year. ## Deliberate Limits on Customer Onboarding Management noted it is intentionally throttling onboarding for certain customer segments, especially SMBs, to protect acquisition economics and ensure product fit. This disciplined approach may constrain near-term customer growth but is designed to support profitability and retention over the longer term. ## Pressure from Hybrid AF and Execution Lag Hybrid AF therapy volumes remain under pressure, though some of the revenue drag is being offset by pricing uplift from AtriClip Pro Mini. The company also highlighted that newly hired senior leaders and expanded sales teams need time to ramp, implying a lag between current investment and the full revenue benefit. ## Guidance Points to Back-Half Acceleration Management’s guidance calls for Q2 revenue of $81 million to $83 million, implying around 20% year-on-year growth at the midpoint, and full-year revenue of $347 million to $357 million, or about 24% growth. Adjusted EBITDA is expected between $96 million and $101 million, with faster BOX NOAF enrollment and upcoming Flex Mini and Pro Mini launches seen as key contributors to the anticipated second-half ramp. MNTN’s earnings call ultimately balanced optimism with realism, highlighting broad-based growth, expanding margins and rapid clinical progress while openly acknowledging pockets of weakness. For investors, the story hinges on whether strong execution, new products and regulatory wins can sustain the guided acceleration and offset pressures in minimally invasive and hybrid AF volumes. ### Related Stocks - [MNTN.US](https://longbridge.com/en/quote/MNTN.US.md) ## Related News & Research - [MNTN, Inc Class A Confronts Rising AI Risk from Costly Development, Data Dependence and Intensifying Competition](https://longbridge.com/en/news/286043090.md) - [Hormel Foods Corporation Declares Quarterly Dividend | HRL Stock News](https://longbridge.com/en/news/286830009.md) - [Oklo Looks Stronger as a Long-Term Energy Play Thanks to 2 Major Growth Drivers](https://longbridge.com/en/news/286923204.md) - [Dogwood Therapeutics Announces Commencement of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension Study | DWTX Stock News](https://longbridge.com/en/news/286772955.md) - [AlzeCure Pharma to Host Live Seminar on The Pain Project TrkA-NAM ACD137 with a Focus on Osteoarthritis and Neuropathic Pain](https://longbridge.com/en/news/286879044.md)